TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Examination and Treatment of Elderly After a Fall- an Analysis in a Medical Technology Evaluation Perspective
Brief Summary: Falls and injurious falls are common among elderly people. The aim of the study is to test a model of multifactorial fall intervention in a Danish population of elderly sustaining a fall. Focus is on prevention of further falls, patients views on fall prevention and a cost-effectiveness analysis.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: multifactorial intervention | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: multifactorial intervention; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Fall prevention course | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Fall prevention course; Assigned to Arm(s): 1
C: Intervention Type: BEHAVIORAL; Name: physical exercise, wellness; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Training | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Intervention Type: BEHAVIORAL; Name: Exercise Training; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Exercise training; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Exercise training; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine
Brief Summary: An observer-blind study to evaluate GlaxoSmithKline Biologicals' live attenuated varicella vaccine and GlaxoSmithKline Biologicals' combined measles-mumps-rubella-varicella vaccine in the prevention of varicella disease in children. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: 13vPnC vaccine; Type: EXPERIMENTAL; Interventions: Biological: 13 valent pneumococcal conjugate vaccine | Arm Label: 7vPnC vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: 7vPnc pneumococcal conjugate vaccine | Intervention Type: BIOLOGICAL; Name: 13 valent pneumococcal conjugate vaccine; Assigned to Arm(s): 13vPnC vaccine | Intervention Type: BIOLOGICAL; Name: 7vPnc pneumococcal conjugate vaccine; Assigned to Arm(s): 7vPnC vaccine
B: Arm Label: MMRV Group; Type: EXPERIMENTAL; Interventions: Biological: Priorix-tetra™ | Arm Label: OKAH Group; Type: EXPERIMENTAL; Interventions: Biological: Priorix™, Biological: Varilrix™ | Arm Label: MMR Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Priorix™ | Intervention Type: BIOLOGICAL; Name: Priorix-tetra™; Assigned to Arm(s): MMRV Group | Intervention Type: BIOLOGICAL; Name: Priorix™; Assigned to Arm(s): MMR Group, OKAH Group | Intervention Type: BIOLOGICAL; Name: Varilrix™; Assigned to Arm(s): OKAH Group
C: Arm Label: ProQuad®; Type: EXPERIMENTAL; Interventions: Biological: ProQuad® | Intervention Type: BIOLOGICAL; Name: ProQuad®; Assigned to Arm(s): ProQuad®
D: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: FluMist | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: FluMist | Intervention Type: BIOLOGICAL; Name: FluMist; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: FluMist; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multi-Centre, Randomised, Double-Blind Comparison of Intravenous Dexmedetomidine With Propofol/Midazolam for Continuous Sedation (24 Hours to 14 Days) of Ventilated Patients in Intensive Care Unit
Brief Summary: The study aims to demonstrate that dexmedetomidine is non-inferior to current best practice sedation with propofol/midazolam and daily sedation stops, in maintaining a target depth of sedation in long-stay intensive care unit (ICU) patients, and that dexmedetomidine, compared with current best practice, reduces the length of ICU stay.


Options:
A: Arm Label: No sedatation intervention; Type: OTHER; Interventions: Procedure: Sedation or no sedation during mechanical ventilation | Intervention Type: PROCEDURE; Name: Sedation or no sedation during mechanical ventilation; Assigned to Arm(s): No sedatation intervention
B: Intervention Type: PROCEDURE; Name: Daily interruption of sedation versus sedation algorithm; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: Sedation management strategy; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multi-Centre, Randomised, Double-Blind Comparison of Intravenous Dexmedetomidine With Propofol/Midazolam for Continuous Sedation (24 Hours to 14 Days) of Ventilated Patients in Intensive Care Unit
Brief Summary: The study aims to demonstrate that dexmedetomidine is non-inferior to current best practice sedation with propofol/midazolam and daily sedation stops, in maintaining a target depth of sedation in long-stay intensive care unit (ICU) patients, and that dexmedetomidine, compared with current best practice, reduces the length of ICU stay.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): 2
B: Arm Label: No sedatation intervention; Type: OTHER; Interventions: Procedure: Sedation or no sedation during mechanical ventilation | Intervention Type: PROCEDURE; Name: Sedation or no sedation during mechanical ventilation; Assigned to Arm(s): No sedatation intervention
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propofol | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase III Trial of Conventional Paclitaxel and Carboplatin Versus Dose Dense Weekly Paclitaxel and Carboplatin in Patients With Newly Diagnosed Stage II-IV Mullerian Carcinoma
Brief Summary: The purpose of the study is to compare progression-free survival of conventional paclitaxel and carboplatin vs weekly paclitaxel and carboplatin in patients with newly diagnosed stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer.


Options:
A: Arm Label: Olaparib tablets p.o. 300mg twice daily; Type: EXPERIMENTAL; Interventions: Drug: Olaparib 300mg tablets | Arm Label: Placebo tablets p.o. twice daily; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olaparib 300mg tablets | Intervention Type: DRUG; Name: Olaparib 300mg tablets; Assigned to Arm(s): Olaparib tablets p.o. 300mg twice daily, Placebo tablets p.o. twice daily
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel+Carboplatin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel+Carboplatin | Intervention Type: DRUG; Name: Paclitaxel+Carboplatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Paclitaxel+Carboplatin; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tamoxifen citrate; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: carboplatin, Drug: paclitaxel | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: carboplatin, Drug: paclitaxel | Intervention Type: PROCEDURE; Name: carboplatin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): B | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)
Brief Summary: To determine the role of pioglitazone in the treatment of nonalcoholic steatohepatitis (NASH) in patients with glucose intolerance or type 2 diabetes mellitus (T2DM).


Options:
A: Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Vitamin E; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone/Vitamin E | Intervention Type: DRUG; Name: Spironolactone/Vitamin E; Assigned to Arm(s): Vitamin E
C: Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A
D: Arm Label: Polypill; Type: EXPERIMENTAL; Interventions: Drug: Polypill | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Polypill; Assigned to Arm(s): Polypill

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)
Brief Summary: To determine the role of pioglitazone in the treatment of nonalcoholic steatohepatitis (NASH) in patients with glucose intolerance or type 2 diabetes mellitus (T2DM).


Options:
A: Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone study drug, Drug: Pioglitazone Open Label | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Pioglitazone Open Label | Intervention Type: DRUG; Name: Pioglitazone study drug; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Pioglitazone Open Label; Assigned to Arm(s): Pioglitazone, Placebo
B: Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder Outpatients With Current Stimulant Dependence
Brief Summary: The purpose of this study is to determine whether quetiapine or risperidone are effective in treating mood symptoms, drug cravings and use in bipolar disorder with concurrent cocaine or methamphetamine dependence.


Options:
A: Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): N/A
B: Arm Label: Risperidone Long Acting; Type: EXPERIMENTAL; Interventions: Drug: Risperidone Long Acting | Arm Label: Oral Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral risperidone | Intervention Type: DRUG; Name: Risperidone Long Acting; Assigned to Arm(s): Risperidone Long Acting | Intervention Type: DRUG; Name: oral risperidone; Assigned to Arm(s): Oral Risperidone
C: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Risperidone Long Acting Injectable (LAI) | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: Quetiapine | Arm Label: 003; Type: OTHER; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Risperidone Long Acting Injectable (LAI); Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): 002
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: quetiapine, risperidone | Intervention Type: DRUG; Name: quetiapine, risperidone; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cornell Translational Behavioral Science Research Consortium: Hypertension Qualitative Study
Brief Summary: To explore the meaning, causes and treatment of hypertension in eligible patients. In addition the cultural, social, and psychological factors that either facilitate or serve, as barriers to behavioral change will be illuminated in this patient population.


Options:
A: Intervention Type: BEHAVIORAL; Name: Semi-structured, open ended interview; Assigned to Arm(s): N/A
B: Intervention Type: PROCEDURE; Name: Therapeutic education; Assigned to Arm(s): N/A
C: Arm Label: Comprehensive Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle Changes, Drug: Antiplatelet Agents, Drug: Beta Blocker, Drug: ACE Inhibitors | Arm Label: Less Intensive Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle Changes | Intervention Type: BEHAVIORAL; Name: Lifestyle Changes; Assigned to Arm(s): Comprehensive Intervention Group, Less Intensive Intervention Group | Intervention Type: DRUG; Name: Antiplatelet Agents; Assigned to Arm(s): Comprehensive Intervention Group | Intervention Type: DRUG; Name: Beta Blocker; Assigned to Arm(s): Comprehensive Intervention Group | Intervention Type: DRUG; Name: ACE Inhibitors; Assigned to Arm(s): Comprehensive Intervention Group
D: Arm Label: Reciprocal Diabetes Peer Support program; Type: EXPERIMENTAL; Interventions: Behavioral: Reciprocal Diabetes Peer Support Program, Behavioral: group outpatient counseling visits | Arm Label: Nurse Case Management; Type: OTHER; Interventions: Behavioral: Nurse Case management | Intervention Type: BEHAVIORAL; Name: Reciprocal Diabetes Peer Support Program; Assigned to Arm(s): Reciprocal Diabetes Peer Support program | Intervention Type: BEHAVIORAL; Name: Nurse Case management; Assigned to Arm(s): Nurse Case Management | Intervention Type: BEHAVIORAL; Name: group outpatient counseling visits; Assigned to Arm(s): Reciprocal Diabetes Peer Support program

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cornell Translational Behavioral Science Research Consortium: Hypertension Qualitative Study
Brief Summary: To explore the meaning, causes and treatment of hypertension in eligible patients. In addition the cultural, social, and psychological factors that either facilitate or serve, as barriers to behavioral change will be illuminated in this patient population.


Options:
A: Intervention Type: BEHAVIORAL; Name: Semi-structured, open ended interview; Assigned to Arm(s): N/A
B: Arm Label: Reciprocal Diabetes Peer Support program; Type: EXPERIMENTAL; Interventions: Behavioral: Reciprocal Diabetes Peer Support Program, Behavioral: group outpatient counseling visits | Arm Label: Nurse Case Management; Type: OTHER; Interventions: Behavioral: Nurse Case management | Intervention Type: BEHAVIORAL; Name: Reciprocal Diabetes Peer Support Program; Assigned to Arm(s): Reciprocal Diabetes Peer Support program | Intervention Type: BEHAVIORAL; Name: Nurse Case management; Assigned to Arm(s): Nurse Case Management | Intervention Type: BEHAVIORAL; Name: group outpatient counseling visits; Assigned to Arm(s): Reciprocal Diabetes Peer Support program
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Cell Phone Intervention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cell Phone Intervention; Assigned to Arm(s): 1
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Depression care management by secure messaging | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Depression care management by secure messaging; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)
Brief Summary: This is a multi-center trial to assess safety and efficacy of a combined regimen of oral valproic acid (VPA) and carnitine in patients with Spinal Muscular Atrophy (SMA) 2 to 17 years of age. Cohort 1 is a double-blind placebo-controlled randomized intention to treat protocol for SMA "sitters" 2 - 8 years of age. Cohort 2 is an open label protocol for SMA "standers and walkers" 3 - 17 years of age to explore responsiveness of efficacy outcomes. Outcome measures will include blood chemistries, functional testing, pulmonary function testing, electrophysiological evaluations, PedsQL quality of life assessment, quantitative assessments of survival motor neuron (SMN) mRNA from blood samples, growth and vital sign parameters. Six centers will enroll a total of 90 patients.


Options:
A: Arm Label: Cohort 1a; Type: PLACEBO_COMPARATOR; Interventions: Drug: Valproic Acid and Levocarnitine, Drug: Placebo | Arm Label: Cohort 1b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valproic Acid and Levocarnitine | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: Valproic Acid and Levocarnitine | Intervention Type: DRUG; Name: Valproic Acid and Levocarnitine; Assigned to Arm(s): Cohort 1a, Cohort 1b, Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1a
B: Arm Label: Nusinersen 6 mg; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Arm Label: Nusinersen 12 mg; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Intervention Type: DRUG; Name: nusinersen; Assigned to Arm(s): Nusinersen 12 mg, Nusinersen 6 mg
C: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: AVXS-101 | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: AVXS-101 | Intervention Type: BIOLOGICAL; Name: AVXS-101; Assigned to Arm(s): Cohort 1, Cohort 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Valproic Acid and Levocarnitine | Intervention Type: DRUG; Name: Valproic Acid and Levocarnitine; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)
Brief Summary: This is a multi-center trial to assess safety and efficacy of a combined regimen of oral valproic acid (VPA) and carnitine in patients with Spinal Muscular Atrophy (SMA) 2 to 17 years of age. Cohort 1 is a double-blind placebo-controlled randomized intention to treat protocol for SMA "sitters" 2 - 8 years of age. Cohort 2 is an open label protocol for SMA "standers and walkers" 3 - 17 years of age to explore responsiveness of efficacy outcomes. Outcome measures will include blood chemistries, functional testing, pulmonary function testing, electrophysiological evaluations, PedsQL quality of life assessment, quantitative assessments of survival motor neuron (SMN) mRNA from blood samples, growth and vital sign parameters. Six centers will enroll a total of 90 patients.


Options:
A: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: AVXS-101 | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: AVXS-101 | Intervention Type: BIOLOGICAL; Name: AVXS-101; Assigned to Arm(s): Cohort 1, Cohort 2
B: Arm Label: Cohort 1a; Type: PLACEBO_COMPARATOR; Interventions: Drug: Valproic Acid and Levocarnitine, Drug: Placebo | Arm Label: Cohort 1b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valproic Acid and Levocarnitine | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: Valproic Acid and Levocarnitine | Intervention Type: DRUG; Name: Valproic Acid and Levocarnitine; Assigned to Arm(s): Cohort 1a, Cohort 1b, Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1a
C: Arm Label: nusinersen; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Intervention Type: DRUG; Name: nusinersen; Assigned to Arm(s): nusinersen
D: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing Outcomes After Colon Surgery: Role of Prehabilitation Facilitating the Recovery Process.
Brief Summary: Most patients find that recovering from surgery is difficult particularly after abdominal surgery for cancer or other intestinal disorders. The surgical stress, healing process and concerns if further treatments are required suggest that the post-operative period may not be the best time to get people to exercise to rehabilitate lost functions. Prehabilitation is the process of enhancing functional capacity of the individual to enable him or her to withstand an incoming stressor, such as surgery, and this study aims to evaluate the effectiveness of prehabilitation for colorectal surgery. Two groups will be formed by a random process and the prehabilitation group will use an exercise cycle and weights to build endurance and strength for a 3-week period prior to surgery. The other group will receive training about exercises that will help them move better after surgery. People who are malnourished prior to surgery will receive nutritional supplements. The results of this trial will be used to inform practitioners and patients alike of the benefits (or risks if any) of exercise in preparing for surgery.


Options:
A: Arm Label: Prehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Exercise Program, Dietary Supplement: Whey Protein Isolate Powder, Behavioral: Relaxation Techniques | Arm Label: Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical Exercise Program, Dietary Supplement: Whey Protein Isolate Powder, Behavioral: Relaxation Techniques | Intervention Type: BEHAVIORAL; Name: Physical Exercise Program; Assigned to Arm(s): Prehabilitation, Rehabilitation | Intervention Type: DIETARY_SUPPLEMENT; Name: Whey Protein Isolate Powder; Assigned to Arm(s): Prehabilitation, Rehabilitation | Intervention Type: BEHAVIORAL; Name: Relaxation Techniques; Assigned to Arm(s): Prehabilitation, Rehabilitation
B: Intervention Type: BEHAVIORAL; Name: Prehabilitation; Assigned to Arm(s): N/A
C: Arm Label: Pre and postoperative exercise; Type: EXPERIMENTAL; Interventions: Other: Physical activity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Physical activity; Assigned to Arm(s): Pre and postoperative exercise
D: Arm Label: Pre-surgery physiotherapy; Type: OTHER; Interventions: Other: Pre-surgery physiotherapy | Arm Label: Waiting-list; Type: OTHER; Interventions: Other: Waiting-list | Intervention Type: OTHER; Name: Pre-surgery physiotherapy; Assigned to Arm(s): Pre-surgery physiotherapy | Intervention Type: OTHER; Name: Waiting-list; Assigned to Arm(s): Waiting-list

Answer: B